PL2417106T3 - Sposób wytwarzania soli pirolidyniowych - Google Patents

Sposób wytwarzania soli pirolidyniowych

Info

Publication number
PL2417106T3
PL2417106T3 PL10713193T PL10713193T PL2417106T3 PL 2417106 T3 PL2417106 T3 PL 2417106T3 PL 10713193 T PL10713193 T PL 10713193T PL 10713193 T PL10713193 T PL 10713193T PL 2417106 T3 PL2417106 T3 PL 2417106T3
Authority
PL
Poland
Prior art keywords
preparing
pyrrolidinium salts
pyrrolidinium
salts
preparing pyrrolidinium
Prior art date
Application number
PL10713193T
Other languages
English (en)
Inventor
Thomas Allmendinger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42200985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2417106(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2417106T3 publication Critical patent/PL2417106T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL10713193T 2009-04-09 2010-04-07 Sposób wytwarzania soli pirolidyniowych PL2417106T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16797709P 2009-04-09 2009-04-09

Publications (1)

Publication Number Publication Date
PL2417106T3 true PL2417106T3 (pl) 2017-05-31

Family

ID=42200985

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10713193T PL2417106T3 (pl) 2009-04-09 2010-04-07 Sposób wytwarzania soli pirolidyniowych

Country Status (14)

Country Link
US (1) US20120022127A1 (pl)
EP (1) EP2417106B1 (pl)
JP (2) JP5902612B2 (pl)
KR (1) KR101290893B1 (pl)
CN (1) CN102388021B (pl)
AU (1) AU2010233772B2 (pl)
BR (1) BRPI1016083A8 (pl)
CA (1) CA2758100C (pl)
ES (1) ES2617680T3 (pl)
MX (1) MX344153B (pl)
PL (1) PL2417106T3 (pl)
PT (1) PT2417106T (pl)
RU (1) RU2554878C2 (pl)
WO (1) WO2010115937A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102939280B (zh) * 2010-06-14 2014-11-19 奇斯药制品公司 格隆氯铵的晶型
CN102627595A (zh) * 2012-03-09 2012-08-08 徐奎 一种制备格隆溴铵的方法
NZ710740A (en) * 2013-02-28 2020-06-26 Dermira Inc Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
CN103553996B (zh) * 2013-11-13 2016-01-20 北京三泉医药技术有限公司 抗胆碱药物组合物
CN103819384A (zh) * 2013-12-05 2014-05-28 广东嘉博制药有限公司 一种格隆溴铵的制备方法
US9926270B2 (en) 2014-08-20 2018-03-27 Dermira, Inc. Process for production of glycopyrronium tosylate
HRP20260435T1 (hr) 2014-09-09 2026-05-08 Vectura Limited Formulacija koja sadrži glikopirolat, postupak i uređaj
CN107304178B (zh) * 2016-04-21 2020-03-27 辽宁药联制药有限公司 一种毒蕈碱受体拮抗剂格隆溴铵手性对映体的制备方法
US10906871B2 (en) 2016-08-02 2021-02-02 Dermira, Inc. Processes for making, and methods of using, glycopyrronium compounds
CN107915666A (zh) * 2016-10-09 2018-04-17 四川海思科制药有限公司 一种格隆溴铵化合物
WO2018167776A1 (en) 2017-03-12 2018-09-20 Sol-Gel Technologies Ltd. Process for the preparation of glycopyrrolate tosylate
US10947191B2 (en) 2017-07-27 2021-03-16 Sol-Gel Technologies Ltd. Process for the preparation of glycopyrrolate tosylate
WO2020148777A1 (en) * 2019-01-14 2020-07-23 Neon Laboratories Limited Process for preparation of glycopyrrolate intermediate
CN111349036B (zh) * 2020-03-13 2022-03-08 安徽恒星制药有限公司 一种格隆溴铵的替代物及其制备方法和医药用途
WO2022079194A1 (en) 2020-10-14 2022-04-21 Pcas Process for the production of glycopyrronium tosylate

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
DE2046659A1 (pl) * 1970-01-28 1972-03-23
FR2081497B1 (pl) * 1970-02-09 1974-08-02 Sandoz Sa
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
US6182655B1 (en) 1995-12-07 2001-02-06 Jago Research Ag Inhaler for multiple dosed administration of a pharmacological dry powder
DK0883415T3 (da) 1996-02-21 2002-08-19 Schering Corp Inhalator til pulverformigt medikament
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ES2206021B1 (es) * 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
AT412088B (de) * 2002-12-18 2004-09-27 Pharmacon Forschung & Beratung Gmbh Verfahren zur herstellung der r,r oder s,s konfigurierten glycopyrronium-isomere
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0504463D0 (en) * 2005-03-03 2005-04-13 Arakis Ltd Method of crystallisation and purification
EP1957451B1 (en) 2005-11-10 2011-10-19 Nicholas S. Bodor Soft anticholinergic zwitterions
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
WO2007077510A2 (en) 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
KR101290893B1 (ko) 2013-07-29
MX344153B (es) 2016-12-07
CA2758100A1 (en) 2010-10-14
BRPI1016083A8 (pt) 2017-10-10
BRPI1016083A2 (pt) 2016-05-10
AU2010233772A1 (en) 2011-10-06
WO2010115937A1 (en) 2010-10-14
RU2011145051A (ru) 2013-05-20
JP2015007081A (ja) 2015-01-15
EP2417106A1 (en) 2012-02-15
CN102388021A (zh) 2012-03-21
JP5902612B2 (ja) 2016-04-13
MX2011010657A (es) 2011-10-21
US20120022127A1 (en) 2012-01-26
EP2417106B1 (en) 2016-11-30
KR20120013370A (ko) 2012-02-14
RU2554878C2 (ru) 2015-06-27
PT2417106T (pt) 2017-02-13
ES2617680T3 (es) 2017-06-19
CA2758100C (en) 2017-08-29
JP2012523390A (ja) 2012-10-04
AU2010233772B2 (en) 2014-04-24
CN102388021B (zh) 2015-02-18

Similar Documents

Publication Publication Date Title
PT2417106T (pt) Processo para preparação de sais de pirrolidínio
IL214600A0 (en) Process for preparing substituted 2-nitrobiphenyls
IL218641A0 (en) Process for preparing azabicyclic compounds
PT2322581E (pt) Processo para preparar hidromagnesite
IL220357A0 (en) Process for preparing substituted 1-o-acyl-2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranoses
IL222290A0 (en) Process for preparing aminobenzofuran derivatives
ZA201102424B (en) Process for preparing 2-alkyl-3-aroyl-5-nitro-benzofurans
IL222191A0 (en) Process for preparing sulfonamido-benzofuran derivatives
PL2390243T3 (pl) Sposób wytwarzania bisfenolu
IL217592A (en) Process for making pingolimod salts
ZA201207386B (en) Process for preparing benzoxaboroles
IL218140A0 (en) Process for preparing 1-phenylpyrazoles
ZA201008350B (en) Process for preparing cycloalkyl-substituted piperazine compounds
ZA201201237B (en) Process for preparing decanecarboxylic acids
IL227220A (en) A process for preparing a history of 3-alkylsulfinylbenzoyl
EP2404985A4 (en) PROCESS FOR PRODUCING LIPID
ZA201109439B (en) Process for preparing alkylalkanolamines
IL208514A0 (en) Process for preparing substituted biphenylanilides
IL210741A0 (en) Process for preparing cycloalkyl-substituted piperazine compounds
EP2456778A4 (en) PROCESS FOR PRODUCING FLUOROCYTIDINE DERIVATIVES
SI2477964T1 (sl) Postopek za pripravo derivatov alfa-karboksamida
IL207222A0 (en) Process for preparing hebivolol
EP2619174A4 (en) PROCESS FOR THE PREPARATION OF L-PHENYL-3-DIMETHYLAMINOPROPANE DERIVATIVES
PL2621896T3 (pl) Sposób wytwarzania disiarczku dimetylu
ZA201204825B (en) Process for preparing biocides